Emerging Data on Chemo-Immunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Brain Metastases

2024 was packed with advances in lung cancer care. What will 2025 hold? The panel shares which potential breakthroughs they are most looking forward to seeing.

ASCO recently released a guideline rapid recommendation update for systemic therapy in patients with SCLC based on results of two key recent clinical trials.

ASCO updated stage III NSCLC treatment guidance after the LAURA trial. But for patients without oncogenic driver mutations, optimal treatment remains unclear.

Lung cancer treatment options greatly expanded this year. Our panel discusses 8 significant approvals by the FDA in “a year packed with lung cancer advancements.”

The FDA approved ensartinib for adults with ALK-mutated locally advanced or metastatic non-small cell lung cancer who have not received prior ALK-targeted therapy.

The FDA rejected a BLA seeking approval for a subcutaneous amivantamab combination for use in EGFR-mutated non-small cell lung cancer.

Dr. Roy Herbst shares the top news in 2024 for non-small cell lung cancer, including key research and emerging treatment strategies.

The FDA granted accelerated approval to zenocutuzumab for adults with NRG1-positive NSCLC or pancreatic adenocarcinoma.

The FDA approved durvalumab for adults with limited-stage small cell lung cancer who have not progressed after chemotherapy and radiation treatment.

2024 has been a big year for SCLC, with “astounding” results from a major clinical trial leading to a new standard of care among the significant developments.

Kamya Sankar, MD, and Robert A. Figlin, MD, discuss how to choose between an “old friend” in osimertinib and new options in EGFR-mutated metastatic NSCLC.

In October, the U.S. Food and Drug Administration fast-tracked several drugs in oncology. Here are highlights in lung, brain, and ovarian cancer and more.